Major domestic corporations will participate in the JP Morgan Healthcare Conference, the first global pharmaceutical and bio event of 2025.
According to the pharmaceutical bio industry on the 6th, major domestic corporations will participate in the JP Morgan Healthcare Conference, a global healthcare event held in San Francisco, United States, from the 13th to the 16th (local time).
This event, held every January, is the largest pharmaceutical and bio investment event in the world, where trends in the global pharmaceutical and bio market for the year, as well as promising technologies possessed by each corporation, can be confirmed in one place. This year's 43rd event is expected to have over 550 companies and around 8,000 investors and industry experts in attendance.
Leading domestic pharmaceutical and bio corporations Samsung Biologics and Celltrion will conduct main track presentations in the Grand Ballroom, the core stage, having received an official invitation from JP Morgan again this year, following last year. JP Morgan officially invites only major companies in the industry, and the Grand Ballroom is reserved for just 27 companies selected from over 550 invited corporations.
This year, Samsung Biologics' CEO John Lim is expected to directly present on the contract development and manufacturing organization (CDMO) capabilities. It appears that the introduction of the 180,000-liter capacity 5th factory, which will be completed in April, and the antibody-drug conjugate (ADC) dedicated manufacturing facility currently under construction, targeting completion within the year, will also be presented.
Celltrion will again be represented by Chairman Seo Jung-jin and his eldest son, CEO Seo Jin-seok. Chairman Seo is expected to directly introduce the competitiveness of the new drug sector, including the ADC anticancer drug pipeline, multi-antibody therapeutics, biosimilars, and the newly entered CDMO business.
Lotte Biologics, Hugel, Bridge Biotherapeutics, CLASSYS, and others will also make presentations. Lotte Biologics is expected to have its new head, CEO James Park, as a presenter, introducing the current status of the Songdo Bio Campus construction and the ADC production facility at the Syracuse Bio Campus in New York.
Several domestic corporations will engage in business partnering meetings. At the global investor relations (IR) session hosted by the Korea Bio Association on the 14th, six companies, including AbClon, Atheon Bio, and Mediwheel, will participate. The Korea Night networking event on the 15th will see 350 domestic and foreign corporations registered to attend.
Onco Inc. Therapeutics, which recently developed the 37th domestically developed new drug 'Zacubo,' aims to enter the global market with the anticancer drug Nesupaparin, which has been designated as a rare drug for pancreatic cancer by the U.S. Food and Drug Administration (FDA). Currently, the substance is undergoing a Phase 2 clinical trial in combination with Keytruda.
ENSCEL plans to meet with investors to discuss not only the CDMO business for cell and gene therapies but also technology exports related to new drug pipelines. AriBio, which is developing an oral dementia treatment, is expected to hold meetings with multinational pharmaceutical companies and investment firms regarding its major pipeline, including the oral Alzheimer's treatment AR1001, which is currently undergoing global Phase 3 trials.
ST Cube, which is developing the immune anticancer drug Nelmastobart, will also attend to discuss technology exports with global pharmaceutical companies. Pharos iBio, an artificial intelligence (AI)-based new drug development company, plans to introduce its leukemia and solid tumor treatments currently under development.